Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Fibrous dysplasia affecting more than one bone. When it is associated with café-au-lait skin pigmentation and endocrine disorders, it is known as McCune-Albright syndrome.
Biomarker and diagnostic research for polyostotic fibrous dysplasia has been reported in the published literature.
4 clinical trials registered, 1 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE4, 1 NA. Research is primarily sponsored by academic and government institutions.
120 publications have been identified in PubMed for polyostotic fibrous dysplasia. Kisho has analyzed 68 by research type. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 29 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:08 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
43%
Research summaries | 16 | 24% |
Laboratory research | 9 | 13% |
Testing and diagnosis research | 5 | 7% |
Disease patterns and progression | 5 | 7% |
Clinical study results | 2 | 3% |
New treatment approaches | 2 | 3% |
Pfirrmann C (2026). [PMID: 40998114](https://pubmed.ncbi.nlm.nih.gov/40998114/). *Orthop Traumatol Surg Res*. [Review / Meta-Analysis]
Karaca MO (2026). [PMID: 41906848](https://pubmed.ncbi.nlm.nih.gov/41906848/). *Jt Dis Relat Surg*. [Diagnostic / Biomarker]
Hu X (2026). [PMID: 40967338](https://pubmed.ncbi.nlm.nih.gov/40967338/). *Joint bone spine*. [Case Report / Case Series]
Gozgec E (2026). [PMID: 41192755](https://pubmed.ncbi.nlm.nih.gov/41192755/). *Neurochirurgie*. [Epidemiology / Natural History]
Sergheraert J (2026). [PMID: 41736047](https://pubmed.ncbi.nlm.nih.gov/41736047/). *Orphanet J Rare Dis*. [Basic Science / Preclinical]
Alarab H (2026). [PMID: 42013948](https://pubmed.ncbi.nlm.nih.gov/42013948/). *J Pediatr Adolesc Gynecol*. [Case Report / Case Series]
Levitsky A (2026). [PMID: 42038812](https://pubmed.ncbi.nlm.nih.gov/42038812/). *JBMR Plus*. [Clinical Trial Publication]
Fathi HR (2026). [PMID: 41847107](https://pubmed.ncbi.nlm.nih.gov/41847107/). *Int J Surg Case Rep*. [Case Report / Case Series]
van der Meulen M (2026). [PMID: 41243074](https://pubmed.ncbi.nlm.nih.gov/41243074/). *Acta neurologica Belgica*. [Case Report / Case Series]
Rouach V (2026). [PMID: 41424908](https://pubmed.ncbi.nlm.nih.gov/41424908/). *JCEM case reports*. [Case Report / Case Series]
AI-curated news mentioning polyostotic fibrous dysplasia
Updated Aug 3, 2026
A recent perspective highlights the significant unmet need for effective treatments in fibrous dysplasia and rare pediatric bone diseases. The article discusses current challenges and the necessity for innovative therapeutic approaches.
A new injectable matrix metalloproteinase-responsive nanoparticle hydrogel scaffold has been developed for sustained local drug delivery in fibrous dysplasia. This innovative approach could enhance treatment efficacy for patients with this rare bone disorder.
A preclinical study investigates the effects of anti-RANKL and Zoledronate therapies in a mouse model of fibrous dysplasia. The findings contribute to understanding potential treatment strategies for this rare bone disorder.